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Objectives: Bronchiectasis (BE) is characterised by permanent dilation of bronchi 
with destruction of elastic and muscular components of their walls. Prophylactic 
antibiotic treatment with acute management of exacerbation episodes is an impor-
tant component of treatment. Currently there are no approved therapies for BE 
and inhaled antibiotics and nebulized solutions are used off-label. The objective 
of this study was to predict clinical and economic consequences associated with 
BE in adult patients over their lifetime. MethOds: We developed a Markov cohort 
model with a cycle length of 4 weeks from UK health care perspective. The model 
included 4 Markov states: one stable disease state defined as confirmed non - cystic 
fibrosis bronchiectasis and without exacerbations in the previous 4 weeks and three 
exacerbation states defined on the basis of severity of exacerbation and associated 
health care resource utilization. Disease state specific costs included costs of drugs, 
consultations/visits, diagnostic test/procedures, physiotherapy, emergency room 
visits and hospitalizations. Patient baseline characteristics, exacerbation rates and 
utilities were estimated from literature. Results: The model suggests that ability to 
reduce hospitalizations and limit impact on quality of life are the major value driv-
ers. The model is also sensitive to baseline risk of exacerbations. A treatment for BE 
that results in 35% reduction in exacerbation rates and related hospitalizations may 
result in a reduction of 15.53 exacerbations and 3.23 hospitalizations per patient 
over lifetime. Reduction in number of hospitalization will result in fewer long-term 
complications, leading to reduction of 1 death per 600 patients over a period of 10 
years. The treatment could result in reduction of medical cost by £10,777 and 0.11 
QALY gain per patient over lifetime. cOnclusiOns: Any health care intervention 
that could reduce the number of exacerbations and related hospitalizations in the 
BE patients can have significant beneficial impact on clinical outcomes, costs and 
quality of life.
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Objectives: Since treatment with biologics may reactivate latent TB, testing and 
prophylaxes before initiating therapy are mandatory. However, there is not a unique 
solution for the number and type of tests to be used for detecting the presence of TB, 
and for the definition of when prophylaxis should be prescribed. Which alternative 
should be preferred depends on the effectiveness of treatment and also on the cost 
associated. This methodological study aims to define a general economic model to 
assess different protocols for latent TB detection in patients undergoing anti-TNF 
treatment. MethOds: A decision tree approach has been designed for comparing 
alternative protocols in terms of (a) expected costs of different strategies for latent 
TB assessment in patients undergoing anti-TNF treatment; b) the economic conveni-
ence of the prophylaxis therapy in presence of a negative chest X-ray. Uncertainty is 
expressed by the probability of being positive and negative to the tests. In the NHS 
perspective the model considers: costs of tests; costs of TB onsets for rheumato-
logic patients who undergo biologics; costs of extending anti TB prophylaxis also 
to false negative patients; costs related to 1-month biologic therapy delay because 
of prophylaxis; costs for adverse events therapy and/or test related. Indirect costs 
are also considered in the broader societal perspective. Results: Costs assessed 
are useful to choose the less costly alternatives. The comparison also considers 
the reduction of false negatives to the tests which do not follow prophylaxis while 
being affected by latent TB. cOnclusiOns: The model, that can represent a useful 
tool both for clinical and health policy decision making, is a general one; it can be 
applied to any country by inserting the country specific epidemiological, clinical, 
and economical data, and to any anti-TNF drug, by using the specific biologic drug-
related risk factor.
PRM50
AN efficieNt DesigN foR cost-effectiveNess stuDies of PeRsoNAlizeD 
MeDiciNe stRAtegies
Leunis A.1, Redekop W.K.2, Lowenberg B.3, Uyl-De Groot C.A.4
1Institute for Medical Techonology Assessment (iMTA), Rotterdam, The Netherlands, 2Erasmus 
University, Rotterdam, The Netherlands, 3Erasmus Medical Center, Rotterdam, The Netherlands, 
4Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The 
Netherlands
Objectives: The aim of this study is to assess how cost-effectiveness analyses of 
personalized medicine approaches (PMA) can be efficiently designed by using a 
case study in the field of acute myeloid leukemia. MethOds: The cost-effective-
ness analysis of the PMA was performed in two steps. As a PMA often only causes a 
treatment change in a specified subgroup of the patients, the cost-effectiveness of 
the identified treatment change was estimated as a first step (restricted analyses). 
Subsequently, a full cost-effectiveness analysis was performed which included 
all patients and the costs of identifying the specified subgroup. The relation-
ship between the full and restricted analyses was evaluated by varying different 
input parameters. Results: It was found that the full cost-effectiveness of a 
PMA approach could be described as a function of the (cost-) effectiveness of the 
treatment change in the specified subgroup, the costs of identifying the subgroup 
and the size of the subgroup. If no additional costs are associated with the iden-
tification of the subgroup, the incremental cost-effectiveness ratio (ICER) of the 
full analysis is identical to the ICER of the restricted analysis. Otherwise, the ICER 
Objectives: Diabetic nephropathy (DN) is a progressive kidney disease that occurs 
in around 40% of patients with diabetes, and the recommended treatment is an 
angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker 
(ARB). Individuals’ health-related quality of life (HRQoL) can be summarised by 
utility values, which reflect preferences for different health states, and are used in 
cost-utility analyses (CUAs). This literature review identified the utilities used in 
CUAs of ACEi/ARB treatment in patients with DN. MethOds: A combined protocol 
was developed to identify CUAs of ACEi/ARB treatment in DN as well as studies 
that estimated utilities in DN (for a separate review). We searched electronic data-
bases (MEDLINE, EMBASE, NHS EED, HEED, CEA Registry, EconLit, RePEc, HTA) from 
1 January 2000 to 31 July 2013. Search results were assessed for relevance by two 
reviewers. For eligible CUAs, data extracted included health states with assigned 
utilities. Results: Of 5236 references identified from the combined search, 28 CUAs 
remained after review of titles/abstracts, and eight after full text review. The CUAs 
assessed treatment (ACEi n= 3; ARB n= 4; both n= 1) in patients with type 1 diabe-
tes (n= 2), type 2 diabetes (n= 4) or unspecified diabetes (n= 2). Seven CUAs used a 
Markov model and one a decision-analysis tree. Health states in the models included 
microalbuminuria, proteinuria, nephropathy, end-stage renal disease (ESRD), non-
ESRD, dialysis and transplant. ESRD was the most frequent, with utilities ranging 
0.53-0.69 (n= 6). Utility data used in the models were sourced from a number of 
different studies. cOnclusiOns: For CUAs of ACEi/ARB therapy in patients with 
DN, few health states were included, and there was variation in values for the same 
health state due to a range of different reference sources being used. It is important 
for future economic models of DN therapies that robust utility values are available 
for included health states.
PRM45
MoDelliNg DePeNDeNce BetweeN DisABility stAtus AND heAlth 
seRvice costs of PeoPle with RheuMAtoiD ARthRitis iN huNgARy
Rakonczai P.1, Nagy B.1, Rojkovich B.2, Gáti T.2
1Healthware Consulting Ltd., Budapest, Hungary, 2Buda Hospital of Hospitaller Brothers of  
St. John, Budapest, Hungary
Objectives: The main objective of this study is to estimate the impact of the level 
of functional status and disability on health service costs related to rheumatoid 
arthritis (RA) disease in Hungary. It is straightforward to think that higher disability 
implies higher costs, where the nature of the relationship is unclear. In order to 
explore the dependence structure a novel approach is proposed. Instead of fitting 
trend lines for the cost by regression methods the entire bivariate distribution was 
modelled. MethOds: Health Assessment Questionnaire’s disability index data 
were collected for 497 RA patients (with 2594 observations) treated in the Arthritis 
Center (AC) Buda Hospital of Hospitaller Brothers of St. John from 1st January 2005 
to 31st July 2013. The same patients were also found in the database of National 
Health Insurance Fund Administration (NHIFA) and further parameters as e.g. 
relevant treatments and health service costs (in- and outpatient) were collected. 
After merging AC and NHIFA database the 2 dimensional patterns of the HAQ-
index measurements versus costs (sum of relevant costs in the following quarter 
year) become available for bivariate modelling. The ingredients were the empiri-
cal distribution of HAQ-index and quarter year cost, and some parametric copula 
families (elliptical or Archimedean) capturing the (possibly non-linear) dependence 
structure. The performance of the different model assumptions were compared by 
goodness-of-fit procedures. Results: The fitted bivariate distribution based on 
the best-performing dependence model are shown in the original “HAQ-index vs. 
cost” scale. The differences of average costs for low/medium/high HAQ-index values 
are summarized and the conditional distribution functions of costs are presented, 
respectively. cOnclusiOns: It has been proved that there is a significant posi-
tive dependence between the disability status of RA and health service costs. The 
dependence cannot be considered as linear but this non-linearity can be tackled 
easily by using copula methods.
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Objectives: To design a user-friendly cost calculator to estimate and project 
health care costs of patients diagnosed with hepatitis C virus (HCV) infection in 
Turkey. MethOds: We used Visual Basic in a Microsoft Excel to program compli-
cated models within an easy-to-use framework for providers and payers to calculate 
pharmacy costs for HCV patients in Turkey. The calculator, first, uses the starting 
year to the end year as an input. The user then enters prevalent and incident patient 
numbers. Medication types, medication names, prescription numbers per year and 
prescription costs per medication are also entered. The calculator allows combina-
tion therapies. Depending on response rates, rates of incident and prevalent patients 
and medications type, prescription rates from 2014 and forward (until 2020) can 
then be calculated and projected. The calculator can be used for any country as 
long as the inputs are available through literature from real-world or simulation 
studies. Results: We used a hypothetical example to project pharmacy costs in 
Turkey in 2014 and 2015. We assumed 10,000 patients in 2014 (20% were assumed to 
be treatment naïve) and expected 2,000 new patients in 2015. We assumed ribavirin 
and telaprevir combination therapy for 2014 treatment naïve patients, and peginter-
feron alfa-2a and ribavirin for prevalent patients. The response and treatment rates 
were assumed at 80% for patients who were eligible for treatment. The recurrence 
rate was assumed to be approximately 10% after treatment. Pharmacy costs for HCV 
were calculated at € 7 million in 2014 and approximately € 2 million in 2015, using 
these rates. cOnclusiOns: The economic burden of HCV in Turkey is significant. 
A simple-to-use calculator that uses real-world data and econometric models to 
estimate health care costs of patients with HCV can help payers and providers to 
make improved evidence-based health care decisions.
